We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has provided a positive administrative acceptance and review notification for the Company's PMA application for its Dovitinib-DRP®
The pivotal studies leading to the RECELL System’s FDA premarket approval (PMA) for the treatment of acute thermal burns demonstrated that the RECELL System treated burns using 97.5 percent less donor skin when used alone in second-degree burns, and 32 pe